Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
Public ClinicalTrials.gov record NCT00991289. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Infection with hepatitis C virus (HCV) can cause liver scarring, or cirrhosis, and this usually occurs more rapidly among people infected with both HCV and human immunodeficiency virus (HIV). People infected with both HCV and HIV have poor response to the current HCV treatments. This phase II pilot study evaluated whether adding a new HCV medication improves response to the current standard HCV treatment with pegylated interferon and ribavirin in people with both HCV and HIV.
Study identification
- NCT ID
- NCT00991289
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 68 participants
Conditions and interventions
Conditions
Interventions
- Nitazoxanide (NTZ) Drug
- Pegylated interferon alfa-2a (PEG) Drug
- Ribavirin (RBV) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2010 (Type not available)
- Primary completion
- Nov 2010 (Actual)
- Completion
- Jan 2012 (Actual)
- Last update posted
- Nov 4, 2021
2010 – 2012
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama Therapeutics CRS | Birmingham | Alabama | 35294-2050 | — |
| UCLA CARE Center CRS | Los Angeles | California | 90035 | — |
| Stanford AIDS Clinical Trials Unit CRS | Palo Alto | California | 94304-5350 | — |
| UCSD Antiviral Research Center CRS | San Diego | California | 92103 | — |
| Ucsf Hiv/Aids Crs | San Francisco | California | 94110 | — |
| Massachusetts General Hospital CRS (MGH CRS) | Boston | Massachusetts | 02114 | — |
| New Jersey Medical School- Adult Clinical Research Ctr. CRS | Newark | New Jersey | 07103 | — |
| Weill Cornell Chelsea CRS | New York | New York | 10011 | — |
| Columbia P&S CRS | New York | New York | 10032 | — |
| Trillium Health ACTG CRS | Rochester | New York | 14607 | — |
| Univ. of Rochester ACTG CRS | Rochester | New York | 14642 | — |
| Chapel Hill CRS | Chapel Hill | North Carolina | 27514 | — |
| Cincinnati Clinical Research Site | Cincinnati | Ohio | 45267-0405 | — |
| MetroHealth CRS | Cleveland | Ohio | 44109 | — |
| Penn Therapeutics, CRS | Philadelphia | Pennsylvania | 19104 | — |
| The Miriam Hospital Clinical Research Site (TMH CRS) CRS | Providence | Rhode Island | 02906 | — |
| Virginia Commonwealth Univ. Medical Ctr. CRS | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00991289, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2021 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00991289 live on ClinicalTrials.gov.